Structure Therapeutics Inc. Sponsored ADR

GPCR Healthcare Biotechnology

In the quarter to June 2026, EPS fell 36.4% and free cash flow fell 119.2%, each against the same quarter a year earlier.

20.95 1.24 −5.59%
Market cap
$1.6B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
20.75 26.16 24.81 14.15

+8 more quarters

Net Debt/EBITDA
11.05 15.84 (38.49) 10.41
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(1.65) 0.19 (1.11) (0.90)
Book value per Share
18.64 19.98 25.61 13.17
Free Cash Flow
(120.07) 14.05 (65.91) (52.57)
Other line items

Show all line items

Columns are period end dates